HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases

Table 1

Patient (groups) demographics.

		Age mean	Age range
All groups	619	51.09	18–92
Group A: BRCA 1 mutation
All	83	47.9	34–64
Premenopausal	53	43.35	34–51
Postmenopausal	30	56.93	48–64
Group B: myomas
All	90	47.10	25–79
Premenopausal	63	42.75	25–52
Postmenopausal	27	57.26	44–79
Group C: nonneoplastic ovarian cysts
All	82	35.4	18–75
Premenopausal	66	30.39	18–53
Postmenopausal	16	56.06	54–75
Group D: inflammatory diseases
All	9	34.67	18–43
Premenopausal	9	34.67	18–43
Postmenopausal	—	—	—
Group E: benign epithelial ovarian tumors
All	35	48.77	18–88
Premenopausal	15	29.27	18–48
Postmenopausal	20	63.4	54–88
Group F: endometrial cancers
All	55	66.7	54–92
Premenopausal	2	43.5	43–44
Postmenopausal	53	68.3	54–92
Group G: other gynecological cancers
All	38	53.84	19–92
Premenopausal	17	37.41	19–51
Postmenopausal	21	67.14	52–92
Group H: endometrial polyps
All	95	52.92	19–83
Premenopausal	40	39.5	19–50
Postmenopausal	55	62.67	49–83
Group M: other cancers (metastatic ovarian tumors)
All	8	62.38	51–78
Premenopausal	—	—	—
Postmenopausal	8	62.38	51–78
Group O: ovarian cancers
All	124	58.23	30–90
Premenopausal	33	44.64	30–65
Postmenopausal	91	63.2	48–90